NASDAQ Soins de santé Biotechnologie VOR

Vor Biopharma Inc.

$ 14.49 -3.53 %

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

CEO: Jean-Paul Kress - https://www.vorbio.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$31.67 118.56 %

Recommandation

Buy

DCF

$ 39.40

Loading data...

VOR vs S&P500

Loading data...

No data available.

Quick ratio

31.15

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-0.21

may indicate that the company is undervalued or has poor growth prospects.

EPS

-70.40

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

87.31 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

-76.08 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

12.22

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-0.02

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-350.26

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
0.36 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
10.57 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.